| Name | Title | Contact Details |
|---|
NovaSom is a privately held diagnostic-service provider for home testing and evaluation of obstructive sleep apnea (OSA). As an innovator and pioneer in our field, we developed the first FDA-cleared device designed for unattended, unassisted patient use for the diagnosis of sleep apnea, with clinically proven equivalence * to conventional polysomnography (PSG). NovaSom works with physicians, private insurers, government and public health organizations to address concerns about the large numbers of individuals with undiagnosed sleep apnea. It is our shared concern that millions of Americans are utilizing more health care resources and incurring greater health care costs because their OSA has not been properly diagnosed or treated. It is also our belief that early diagnosis and treatment of OSA can improve lives and help hold down health care costs. Our mission is to improve the health care and quality of life of those impacted by sleep disorders through innovative diagnostic services and by promoting adherence to prescribed therapies.
Future Diagnostics Group is a Joliet, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.
Biomed Clinical Laboratories is a Elmwood Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Good Start Genetics is an innovative molecular diagnostics company harnessing a powerful, proprietary next-generation DNA sequencing (NGS) capability combined with other technologies to deliver best-in-class tests for routine genetic screening. Through its GoodStart Select(TM) offering, the company provides the most comprehensive and clinically actionable set of tests for known and novel mutations that cause inherited diseases. Good Start`s NGS capabilities can be applied to multiple disease areas, including pre-conception carrier screening in the in-vitro fertilization setting.